Better apart: a la Abbott, Baxter split in two
This article was originally published in Scrip
Baxter International is splitting into two companies – one focused on biopharmaceuticals and the other on medical products. In much the same way and citing the same "compelling rationale" that Abbott did just over two years, chairman and CEO Robert Parkinson says the two businesses have unique growth prospects, investment requirements and risk profiles that would be best served separately (scripintelligence.com, 19 October 2011).
You may also be interested in...
The XinThera deal gives Gilead multiple PARP1 and MK2 inhibitors. Also, Roche licenses a HER2 kinase inhibitor from Zion, Amgen partners with TScan in Crohn’s disease and Baxter sells the last of its biopharma operations – a CDMO business – for $4.5bn.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.